{"id":249792,"date":"2026-03-31T00:00:00","date_gmt":"2026-03-31T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0013-2024-biopharma-biosimilars-forecast-endocrinology\/"},"modified":"2026-04-18T23:09:20","modified_gmt":"2026-04-18T23:09:20","slug":"biosbi0013-2026-biopharma-biosimilars-forecast-endocrinology","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0013-2026-biopharma-biosimilars-forecast-endocrinology\/","title":{"rendered":"Biosimilars &#8211; Forecast &#8211; Endocrinology"},"content":{"rendered":"<p>In 2024, sales of branded biologics for endocrinology indications (insulins and antiresorptive analogues) exceeded $22 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2024-2034 forecast period, we expect biosimilar launches to erode both brand share and prices. By 2034, we forecast major-market insulins\u00a0to reach sales of $21 billion, with $11 billion from biosimilars, authorized generics, and follow-on insulins\u2014primarily in the United States. For antiresorptive analogues we forecast sales of $6.5 billion for 2034, with $4 billion from biosimilars and authorized generics. Although U.S. regulatory alignment under the BLA 351(k) pathway simplified classification, development remains capital-intensive due to manufacturing scale, device requirements, and commercial complexity.<\/p>\n","protected":false},"template":"","class_list":["post-249792","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":4,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249792\/revisions"}],"predecessor-version":[{"id":578220,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249792\/revisions\/578220"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}